Prevalence of phosphatidylinositol-3-kinase (PI3K) pathway alterations and co-alteration of other markers in breast cancer

被引：0
|
作者：
Khoury, Katia [1 ]
Tan, Antoinette [2 ]
Elliott, Andrew [3 ]
Xiu, Joanne [3 ]
Gatalica, Zoran [3 ]
Heeke, Arielle L. [2 ]
Isaacs, Claudine [1 ]
Pohlmann, Paula R. [1 ]
Schwartzberg, Lee S. [4 ]
Simon, Michael [5 ]
Korn, Michael W. [3 ]
Swain, Sandra M. [1 ]
Lynce, Filipa [1 ]
机构：
[1] Medstar Georgetown Univ Hosp, Washington, DC USA
[2] Levine Canc Inst, Charlotte, NC USA
[3] Caris Life Sci, Phoenix, AZ USA
[4] West Canc Ctr, Memphis, TN USA
[5] Karmanos Canc Inst, Detroit, MI USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P4-09-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-09-04
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer
    Khoury, Katia
    Tan, Antoinette R.
    Elliott, Andrew
    Xiu, Joanne
    Gatalica, Zoran
    Heeke, Arielle L.
    Isaacs, Claudine
    Pohlmann, Paula R.
    Schwartzberg, Lee S.
    Simon, Michael
    Korn, W. Michael
    Swain, Sandra M.
    Lynce, Filipa
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [2] Role of phosphatidylinositol-3-kinase (PI3K) in cardioprotection.
    Steenbergen, C
    Tong, HY
    Murphy, E
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2003, 35 (06) : A10 - A10
  • [3] Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors
    Hanlon, Ashley
    Brander, Danielle M.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2020, (01) : 346 - 356
  • [4] Diosgenin inhibits melanogenesis through the activation of phosphatidylinositol-3-kinase pathway (PI3K) signaling
    Lee, Jongsung
    Jung, Kwangseon
    Kim, Yeong Shik
    Park, Deokhoon
    LIFE SCIENCES, 2007, 81 (03) : 249 - 254
  • [5] Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology
    Curigliano, Giuseppe
    Shah, Rashmi R.
    DRUG SAFETY, 2019, 42 (02) : 247 - 262
  • [6] Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology
    Giuseppe Curigliano
    Rashmi R. Shah
    Drug Safety, 2019, 42 : 247 - 262
  • [7] Phosphatidylinositol 3-Kinase (PI3K) Pathway Activation in Breast Cancer Brain Metastases
    Anders, C. K.
    Adamo, B.
    Deal, A. M.
    Livasy, C. A.
    Meng, H.
    Burrows, E.
    Fritchie, K.
    Blackwell, K. L.
    Geradts, J.
    Ewend, M. G.
    Carey, L. A.
    Miller, R.
    CANCER RESEARCH, 2010, 70
  • [8] Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
    Knowles, Margaret A.
    Platt, Fiona M.
    Ross, Rebecca L.
    Hurst, Carolyn D.
    CANCER AND METASTASIS REVIEWS, 2009, 28 (3-4) : 305 - 316
  • [9] Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
    Margaret A. Knowles
    Fiona M. Platt
    Rebecca L. Ross
    Carolyn D. Hurst
    Cancer and Metastasis Reviews, 2009, 28 : 305 - 316
  • [10] Prognostic implications of phosphatidylinositol 3-kinase (PI3K) pathway alterations in metastatic triple-negative breast cancer (mTNBC).
    Oliveira, M.
    De Mattos-Arruda, L.
    Sanchez-Olle, G.
    Grana, B.
    Cortes, J.
    Perez-Garcia, J. M.
    Munoz-Consuelo, E.
    Vidal, M.
    Bellet, M.
    Di Cosimo, S.
    Gomez Pardo, P.
    Rodon Ahnert, J.
    Hernandez-Losa, J.
    Vivancos, A.
    Prudkin, L.
    Aura, C.
    Serra, V.
    Baselga, J.
    Tabernero, J.
    Saura, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345